Clinical Trial News | Discover the new PCSK9-I

Exom starts an observational prospective multicenter study to assess the long-term effectiveness and tolerability of a new  PCSK9-I inhibitor in the real life clinical practice, in a severe hypercholesterolemic population resistant to full dosage statins. The study...
Global Health & Pharma Excellence AwardsAward Winner 2022

Exom is proud to announce that Global Health & Pharma has awarded us the 2022 Global Excellence Award as "Most innovative Full-Service CRO - 2022" for our pioneering, cutting-edge use of technology in clinical trials to support study stakeholders.